Fabrication and evaluation of selegiline HCl embedded transdermal film for management of Parkinson’s disease
Purpose: Selegiline HCl (SGN) is indicated for treatment of Parkinson’s disease (PD). Its mode of action involves inhibition of MAO-B enzyme. It shows extensive hepatic first-pass metabolism and low biological half-life of 1.2 -2 hours. It results in 10 % bioavailability on oral administration. To circumvent these problems, it was envisaged to develop transdermal film of selegiline HCl for management of PD.
Method: The transdermal film were developed using ethyl-vinyl acetate (EVA) as a film former. Dibutyl phthalate (DBT) and triethyl citrate (TEC) were used as plasticizers in concentrations 10 to 20 % of polymer weight. Oleic acid and linoleic acid were used as penetration enhancers in concentrations 0.5 to 2 %. Effect of concentration of plasticizers and penetration enhancers were investigated on ex-vivo skin permeation of SGN. The films were subjected to evaluation parameters like weight variation, thickness, drug content, skin irritancy and stability studies.
Results: The transdermal film containing 20 % w/w of TEC of polymer weight has resulted in smooth flexible film. Maximum drug diffusion in ex-vivo permeation was observed. The transdermal film containing 2 % w/w of linoleic acid has shown maximum dug diffusion in ex-vivo permeation studies.
Conclusion: SGN embedded transdermal films were successfully developed using EVA as a film former. TEC and linoleic acid has shown enhanced skin diffusion of drug as compared to DBT and oleic acid. Hence it is a promising approach for transdermal delivery of SGN.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).